FDA chides Amgen over misleading banner ad for Neulasta

In its second untitled letter of 2021, the FDA’s Office of Prescription Drug Promotion raised questions about Amgen’s misleading banner ads for its blockbuster bone marrow stimulant Neulasta.

OPDP notes that certain claims and presentations in the ads, which Amgen said were directed at health care...

Click to view original post